Asthma - A breathless existence

Asthma is now said to affect nearly 25 million people in the U.S. alone (that's one in eight individuals), 300 million worldwide. It continues to increase annually. An estimated $48.6 billion are spent in medical bills, $6 billion in prescription drugs, and who knows how much in alternative treatments - practitioner-based or supplement-based. It has increased by 48 percent in the past 10 years, according to the American Lung Association August 2012 statistics.....

Read more at cdapress.com



The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology's CYT003 for the Treatment of Allergic Asthma

Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. The data are published in the March issue of The Journal of Allergy and Clinical Immunology (JACI) in the article entitled "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma" by Kai-Michael Beeh , MD, et al. (J Allergy Clin Immunol. 2013 Mar;131(3):866-874).....

Read more: prnewswire.com